Symbiotec Pharmalab IPO GMP Today: Date, Price, and Listing Date
Symbiotec Pharmalab IPO opened on August 24, 2026, with a price band of ₹938 to ₹988. Check the latest GMP, subscription status, IPO timeline, financials and peer comparison.
Symbiotec Pharmalab IPO GMP Overview: Symbiotec Pharmalab IPO, worth ₹1,757.00 Cr, will open for subscription from 24 Aug to 27 Aug 2026. Symbiotec Pharmalab allotment is expected on 28 Aug, and shares are likely to be listed on BSE & NSE on 1 Sep 2026. The price band for Symbiotec Pharmalab IPO is set between ₹938 to ₹988
Symbiotec Pharmalab IPO GMP: Symbiotec Pharmalab is a pharmaceutical and biotechnology company that manufactures APIs, nutritional ingredients and specialty products for domestic and international markets.
The company is coming up with a ₹1,757.00 Cr IPO, which will be a combination of fresh issue and OFS. Here are the key details of the Symbiotec Pharmalab IPO.
Symbiotec Pharmalab IPO Details
Here are the listing dates and important details investors should know about the upcoming IPO in Aug.
-
Symbiotec Pharmalab IPO is worth ₹₹1,757.00 cr, and the issue is a combination of a fresh issue of ₹150 cr and offer for sale of ₹1,607 cr.
-
Symbiotec Pharmalab IPO will open for subscription on 24 Aug 2026 and close on 27 Aug 2026. The price band is set between ₹938 to ₹988
-
Symbiotec Pharmalab IPO’s allotment is likely to take place on 28 Aug 2026 and the shares are expected to be listed on BSE and NSE on 1 Sep 2026.
-
The promoter and Promoter Group currently hold 34.47%, which will come down after the listing.
-
The company proposes to use ₹112.50 crore for debt repayment, and the balance for general corporate purposes.
-
MUFG Intime India Pvt.Ltd will be the registrar for the Symbiotec Pharmalab IPO.
|
Parameter |
Detail |
|---|---|
|
IPO Open Date |
24 Aug 2026 |
|
IPO Close Date |
27 Aug 2026 |
|
Expected Allotment Date |
28 Aug 2026 |
|
Expected Listing Date |
1 Sep 2026 (BSE & NSE) |
|
Price Band |
₹938 to ₹988 per share |
|
Lot Size |
15 shares |
|
Minimum Investment |
₹14,820 |
|
Fresh Issue |
₹150 Cr |
|
Offer for Sale (OFS) |
₹1607 Cr |
|
Total Issue Size |
₹1,757 Cr |
Symbiotec Pharmalab IPO GMP Today
Symbiotec Pharmalab IPO GMP today (25th Aug 2026) stands at ₹350, up 35.43% from its upper price band of ₹988 in the grey market (as per investor gain). GMP figures change daily based on market sentiment and demand for the IPO.
GMP figures are for news purposes only. We neither trade nor recommend trading in the grey market.
Investors should note the grey market premium is unofficial & not regulated by SEBI. GMP reflects only informal market trends and should not be considered a reliable indicator of listing gains.
Symbiotec Pharmalab IPO Day 2 Subscription Status
Symbiotec Pharmalab IPO was subscribed 0.85 times on Day 1, as of 7:58 PM.
Symbiotec Pharmalab IPO was subscribed 1.74 times on Day 1, as of 3:50 PM.
|
Date |
QIB (Ex Anchor) |
NII |
Retail |
EMP |
Total |
|---|---|---|---|---|---|
|
24 Aug (Day 1) |
0.37 |
1.10 |
1.01 |
1.65 |
0.85 |
|
25 Aug (Day 2) |
0.57 |
2.59 |
2.04 |
2.86 |
1.74 |
|
27 Aug (Day 3) |
upcoming |
upcoming |
upcoming |
upcoming |
upcoming |
Source: NSE, as of 25th Aug 2026, 3:49 PM
About Symbiotec Pharmalab IPO
Incorporated in 2002, Symbiotec Pharmalab is a pharmaceutical and biotechnology company that makes APIs, nutritional ingredients and specialty products for Indian and overseas markets.
With over 30 years of industry experience, the company has grown from a small-scale steroidal hormone API manufacturer in 1995 into an integrated manufacturing business. It holds approvals from US FDA, EU-GMP, South Korea’s Ministry of Food and Drug Safety and other global regulators.
The company focuses on research, quality standards and sustainable manufacturing. Its products serve the pharmaceutical, nutraceutical and wellness industries.
READ THIS: Augmont Enterprises IPO GMP Today
Symbiotec Pharmalab IPO Reservation
For Symbiotec Pharmalab IPO, 35% of the issue has been reserved for retail investors. The table below shows the allocation across different investor categories.
|
Investor Category |
Shares Offered |
|---|---|
|
QIB Investors |
50% |
|
Retail Investors |
35% |
|
NII (HNI) Investors |
15% |
Symbiotec Pharmalab IPO Lot Size
Retail investors can apply for a minimum of 1 lot, which includes 15 shares costing ₹14,820. Maximum investment allowed for retail investors is 13 lots, which totals 195 shares and costs ₹1,92,660
|
Application |
Lots |
Shares |
Amount (₹) |
|---|---|---|---|
|
Retail (Min) |
1 |
15 |
14,820 |
|
Retail (Max) |
13 |
195 |
1,92,660 |
|
S-HNI (Min) |
14 |
210 |
2,07,480 |
|
S-HNI (Max) |
67 |
1,005 |
9,92,940 |
|
B-HNI (Min) |
68 |
1,020 |
10,07,760 |
Symbiotec Pharmalab IPO Financial Performance
Symbiotec Pharmalab reported a PAT of ₹ 109.90 Cr as of 31 March 2026, up from ₹100.06 Cr in FY24. Over the past 3 years, the company’s PAT and PAT margin have grown steadily. All financial details are provided in the table below.
|
Period Ended |
31 Mar 2026 |
31 Mar 2025 |
31 Mar 2024 |
|---|---|---|---|
|
Revenue from Ops (₹ Cr) |
869.15 |
751.55 |
716.25 |
|
Total Income (₹ Cr) |
872.26 |
755.98 |
723.33 |
|
EBITDA (₹ Cr) |
231.97 |
206.11 |
177.04 |
|
EBITDA Margin (%) |
26.59 |
27.26 |
24.48 |
|
PAT (₹ Cr) |
109.90 |
96.79 |
100.06 |
|
PAT Margin (%) |
12.60 |
12.80 |
13.83 |
|
ROE (%) |
11.19 |
12.66 |
14.98 |
|
ROCE (%) |
11.56 |
11.80 |
14.03 |
Source: Symbiotec Pharmalab IPO RHP
Symbiotec Pharmalab IPO Peer Comparison from RHP
Symbiotec Pharmalab IPO has a decent EPS among its peers. Higher EPS is always considered better. Below is a brief comparison of Symbiotec Pharmalab IPO.
|
Company |
EPS Diluted |
P/E (X) |
|---|---|---|
|
Laurus Labs |
16.45 |
109.36 |
|
Cohance Lifesciences |
4.68 |
95.02 |
|
Divi's Laboratories |
96.75 |
87.8 |
|
Concord Biotech |
24.78 |
61.07 |
|
Symbiotec Pharmalab |
19 |
— |
Source: RHP
Conclusion
Symbiotec Pharmalab IPO is drawing interest in the grey market on August 24, 2026, with the company showing healthy profit margins. However, investors should look beyond GMP and evaluate the IPO based on its valuation, financial performance, business risks and comparison with listed peers.
All topics
Click the link, confirm the box next to sahi.com is checked — ignore any other results.